Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3B randomized double-blind double-dummy comparison of abrocitinib vs dupilumab in adults with moderate to severe atopic dermatitis
2019-004013-13Phase 3Unknown
- Sponsor
- Pfizer
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Abrocitinib arm with Dupixent arm (2 arms). Primary endpoint: PP-NRS4 response at Week 2. Status: unknown.
02
Drugs
abrocitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2019-004013-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004013-13.